3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
4
NIH
3
NETWORK
2
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sleep Initiation and Maintenance Disorders
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Irinotecan
6
S 1 (combination)
4
Oxaliplatin
3
palbociclib
2
durvalumab
2
Tamoxifen
2
Radiation
2
Erlotinib Hydrochloride
2
Cetuximab
2
Capecitabine
2
tremelimumab
1
trametinib
1
titanium silicide
1
sintilimab
1
olaparib
1
nilotinib
1
glasdegib
1
genexol-PM
1
futibatinib
1
dabrafenib
1
ceritinib
1
capmatinib
1
anlotinib
1
Temozolomide
1
Talc
1
Surgical Procedures, Operative
1
Radiosurgery
1
Pancreatectomy
1
Paclitaxel
1
Methylene Blue
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Neoplasm Metastasis
×
Filgrastim
×
Clear all
NCT00557102
2012-12-11
ERBIFORT
National Cancer Institute, France
Phase 2
Completed
24 enrolled